Effect of Nitric Oxide Pathway Inhibition on the Evolution of Anaphylactic Shock in Animal Models: A Systematic Review

Simple Summary Anaphylactic shock (AS) is the most serious consequence of anaphylaxis, with life-threatening sequelae including hypovolemia, shock, and arrhythmias. The literature lacks evidence for the effectiveness of interventions other than epinephrine in the acute phase of anaphylaxis. Our objective was to assess, through a systematic review, how inhibition of nitric oxide (NO) pathways affects blood pressure, and whether such blockade improves survival in AS animal models. AS was induced in all included studies after or before drug administration that targeted blockade of the NO pathway. In all animal species studied, the induction of AS caused a reduction in arterial blood pressure. However, the results show different responses to the inhibition of nitric oxide pathways. Overall, seven of fourteen studies using inhibition of nitric oxide pathways as pre-treatment before induction of AS showed improvement of survival and/or blood pressure. Four post-treatment studies from eight also showed positive outcomes. This review did not find strong evidence to propose modulation of blockade of the NO/cGMP pathway as a definitive treatment for AS in humans. Well-designed in vivo AS animal pharmacological models are needed to explore the other pathways involved, supporting the concept of pharmacological modulation. Abstract Nitric oxide (NO) induces vasodilation in various types of shock. The effect of pharmacological modulation of the NO pathway in anaphylactic shock (AS) remains poorly understood. Our objective was to assess, through a systematic review, whether inhibition of NO pathways (INOP) was beneficial for the prevention and/or treatment of AS. A predesigned protocol for this systematic review was published in PROSPERO (CRD42019132273). A systematic literature search was conducted till March 2022 in the electronic databases PubMed, EMBASE, Scopus, Cochrane and Web of Science. Heterogeneity of the studies did not allow meta-analysis. Nine hundred ninety unique studies were identified. Of 135 studies screened in full text, 17 were included in the review. Among six inhibitors of NO pathways identified, four blocked NO synthase activity and two blocked guanylate cyclase downstream activity. Pre-treatment was used in nine studies and post-treatment in three studies. Five studies included both pre-treatment and post-treatment models. Overall, seven pre-treatment studies from fourteen showed improvement of survival and/or arterial blood pressure. Four post-treatment studies from eight showed positive outcomes. Overall, there was no strong evidence to conclude that isolated blockade of the NO/cGMP pathway is sufficient to prevent or restore anaphylactic hypotension. Further studies are needed to analyze the effect of drug combinations in the treatment of AS.

[1]  P. Evora,et al.  Indigo Carmine Hemodynamic Studies to Treat Vasoplegia Induced by Compound 48/80 in a Swine Model of Anaphylaxis , 2022, Brazilian journal of cardiovascular surgery.

[2]  A. Muraro,et al.  EAACI guidelines: Anaphylaxis (2021 update) , 2021, Allergy.

[3]  J. Yusin,et al.  Mechanisms Governing Anaphylaxis: Inflammatory Cells, Mediators, Endothelial Gap Junctions and Beyond , 2021, International journal of molecular sciences.

[4]  E. Mayo-Wilson,et al.  The PRISMA 2020 statement: an updated guideline for reporting systematic reviews , 2021, BMJ.

[5]  A. Muraro,et al.  EAACI guideline: Preventing the development of food allergy in infants and young children (2020 update) , 2021, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.

[6]  Heather B. Blunt,et al.  PRISMA-S: an extension to the PRISMA Statement for Reporting Literature Searches in Systematic Reviews , 2021, Systematic Reviews.

[7]  P. Evora,et al.  Effects of NO/cGMP inhibitors in a rat model of anaphylactoid shock , 2013, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.

[8]  O. Collange,et al.  Treatment with a platelet‐activating factor receptor antagonist improves hemodynamics and reduces epinephrine requirements, in a lethal rodent model of anaphylactic shock , 2019, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[9]  M. Sahebazamani,et al.  USE OF METHYLENE BLUE IN REFRACTORY ANAPHYLAXIS MAY PREVENT A CATASTROPHIC INTUBATION , 2019, Chest.

[10]  S. Alper,et al.  Cellular and Immunohistochemical Changes in Anaphylactic Shock Induced in the Ovalbumin-Sensitized Wistar Rat Model , 2019, Biomolecules.

[11]  P. Furtado,et al.  Methylene Blue to Treat Refractory Latex-Induced Anaphylactic Shock: A Case Report. , 2017, A&A practice.

[12]  M. Tanida,et al.  Renal response to anaphylaxis in anesthetized rats and isolated perfused rat kidneys: roles of nitric oxide , 2017, The Journal of Physiological Sciences.

[13]  A. Oulhaj,et al.  4-Aminopyridine, A Blocker of Voltage-Dependent K+ Channels, Restores Blood Pressure and Improves Survival in the Wistar Rat Model of Anaphylactic Shock , 2016, Critical care medicine.

[14]  P. Evora,et al.  Methylene Blue to Treat Protamine-induced Anaphylaxis Reactions. An Experimental Study in Pigs , 2016, Brazilian journal of cardiovascular surgery.

[15]  Joyce E. Yu,et al.  The Epidemiology of Anaphylaxis , 2018, Clinical Reviews in Allergy & Immunology.

[16]  M. Rovers,et al.  SYRCLE’s risk of bias tool for animal studies , 2014, BMC Medical Research Methodology.

[17]  A. Nemmar,et al.  Glyburide, a K+ATP channel blocker, improves hypotension and survival in anaphylactic shock induced in Wistar rats sensitized to ovalbumin. , 2013, European journal of pharmacology.

[18]  M. Tanida,et al.  Nitric oxide and β2-adrenoceptor activation attenuate pulmonary vasoconstriction during anaphylactic hypotension in anesthetized BALB/c mice , 2013, Experimental lung research.

[19]  O. Collange,et al.  Methylene Blue and Epinephrine: A Synergetic Association for Anaphylactic Shock Treatment* , 2013, Critical care medicine.

[20]  P. Vadas,et al.  Methylene blue for the treatment of refractory anaphylaxis without hypotension. , 2013, The American journal of emergency medicine.

[21]  I. Bernátová,et al.  L-NAME in the cardiovascular system — nitric oxide synthase activator? , 2012, Pharmacological reports : PR.

[22]  F. Finkelman,et al.  Intestinal mast cell levels control severity of oral antigen-induced anaphylaxis in mice. , 2012, The American journal of pathology.

[23]  P. Evora,et al.  Methylene blue administration in the compound 48/80-induced anaphylactic shock: hemodynamic study in pigs. , 2011, Acta cirurgica brasileira.

[24]  Takao Shimizu,et al.  Mouse and human neutrophils induce anaphylaxis. , 2011, The Journal of clinical investigation.

[25]  Calman Prussin,et al.  IgE, mast cells, basophils, and eosinophils. , 2003, The Journal of allergy and clinical immunology.

[26]  Y. Kurata,et al.  7-NITROINDAZOLE, BUT NOT L-NAME OR AMINOGUANIDINE, ATTENUATES ANAPHYLACTIC HYPOTENSION IN CONSCIOUS RATS , 2009, Shock.

[27]  S. Stawicki,et al.  Methylene blue and vasoplegia: who, when, and how? , 2008, Mini reviews in medicinal chemistry.

[28]  A. Cauwels.  Nitric oxide in shock. , 2007, Kidney international.

[29]  P. Evora,et al.  Methylene blue for clinical anaphylaxis treatment: a case report. , 2007, Sao Paulo medical journal = Revista paulista de medicina.

[30]  Wei Liu,et al.  N(G)-nitro-L-arginine methyl ester, but not methylene blue, attenuates anaphylactic hypotension in anesthetized mice. , 2007, Journal of pharmacological sciences.

[31]  Ben Janssen,et al.  Anaphylactic shock depends on PI3K and eNOS-derived NO. , 2006, The Journal of clinical investigation.

[32]  John W. Clark,et al.  Mathematical modeling of the nitric oxide/cGMP pathway in the vascular smooth muscle cell. , 2005, American journal of physiology. Heart and circulatory physiology.

[33]  C. Piccinato,et al.  THE USE OF METHYLENE BLUE IN THE TREATMENT OF ANAPHYLACTIC SHOCK INDUCED BY COMPOUND 48/80: EXPERIMENTAL STUDIES IN RABBITS , 2005, Shock.

[34]  M. Yokoyama,et al.  Role of nitric oxide in anaphylactic shock , 1995, Journal of Clinical Immunology.

[35]  P. Evora,et al.  [Methylene blue to treat anaphylaxis during anesthesia: case report.]. , 2004, Revista brasileira de anestesiologia.

[36]  P. Evora,et al.  Methylene blue: an effective treatment for contrast medium-induced anaphylaxis. , 2003, Medical science monitor : international medical journal of experimental and clinical research.

[37]  Z. Vered,et al.  LINCS: L-NAME (a NO synthase inhibitor) in the treatment of refractory cardiogenic shock: a prospective randomized study. , 2003, European heart journal.

[38]  D. Longrois,et al.  Constitutive Nitric Oxide Synthase Inhibition Combined with Histamine and Serotonin Receptor Blockade Improves the Initial Ovalbumin-Induced Arterial Hypotension but Decreases the Survival Time in Brown Norway Rats Anaphylactic Shock , 2003, Shock.

[39]  E. Masini,et al.  Protective effect of relaxin in cardiac anaphylaxis: involvement of the nitric oxide pathway , 2002, British journal of pharmacology.

[40]  H. Bruining,et al.  Effect of L-NAME, an inhibitor of nitric oxide synthesis, on cardiopulmonary function in human septic shock. , 1998, Chest.

[41]  C. Nathan,et al.  Perspectives Series : Nitric Oxide and Nitric Oxide Synthases Inducible Nitric Oxide Synthase : What Difference Does It Make ? , 2013 .

[42]  P. Evora,et al.  Methylene blue in anaphylactic shock. , 1997, Annals of emergency medicine.

[43]  Hong-Gang Wang,et al.  Participation of nitric oxide in the sympathetic response to anaphylactic hypotension in anesthetized dogs , 1996, Neuroscience Letters.

[44]  R. F. Davis,et al.  Indigo carmine inhibits endothelium-dependent and -independent vasodilation. , 1996, Hypertension.

[45]  R. Shimizu,et al.  NITRIC OXIDE SYNTHASE INHIBITION IS DETRIMENTAL TO CARDIAC FUNCTION AND PROMOTES BRONCHOSPASM IN ANAPHYLAXIS IN RABBITS , 1995, Shock.

[46]  P. Libby,et al.  Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. , 1995, The Journal of clinical investigation.

[47]  R. Shimizu,et al.  An inhibitor of nitric oxide synthase, N omega-nitro-L-arginine-methyl ester, attenuates hypotension but does not improve cardiac depression in anaphylaxis in dogs. , 1995, Shock.

[48]  H. Oku,et al.  Participation of nitric oxide in mouse anaphylactic hypotension. , 1994, European journal of pharmacology.

[49]  H. Saito,et al.  NG-methyl-L-arginine, an inhibitor of L-arginine-derived nitric oxide synthesis, stimulates renal sympathetic nerve activity in vivo. A role for nitric oxide in the central regulation of sympathetic tone? , 1992, Circulation research.

[50]  P. Vallance,et al.  Effect of nitric oxide synthase inhibitors on hypotension in patients with septic shock , 1991, The Lancet.

[51]  S. Amir,et al.  An inhibitor of nitric oxide production, NG-nitro-L-arginine-methyl ester, improves survival in anaphylactic shock. , 1991, European journal of pharmacology.